200 related articles for article (PubMed ID: 35397172)
21. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
22. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
[TBL] [Abstract][Full Text] [Related]
24. [Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine].
Andersen SE; Paulsen NH; Pfeiffer P; Qvortrup C; Damkier P
Ugeskr Laeger; 2021 Feb; 183(6):. PubMed ID: 33570023
[TBL] [Abstract][Full Text] [Related]
25.
Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
[TBL] [Abstract][Full Text] [Related]
26. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B; Launay M; Ciccolini J; Derain L; Parant F; Thomas F; Guitton J
ESMO Open; 2023 Jun; 8(3):101577. PubMed ID: 37267808
[TBL] [Abstract][Full Text] [Related]
27. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
[TBL] [Abstract][Full Text] [Related]
28. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
29. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
Saarenheimo J; Wahid N; Eigeliene N; Ravi R; Salomons GS; Ojeda MF; Vijzelaar R; Jekunen A; van Kuilenburg ABP
Cancer Chemother Pharmacol; 2021 May; 87(5):657-663. PubMed ID: 33544210
[TBL] [Abstract][Full Text] [Related]
30. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
31. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Casneuf V; Borbath I; Van den Eynde M; Verheezen Y; Demey W; Verstraete AG; Bm Claes K; Haufroid V; Geboes KP
Acta Clin Belg; 2022 Apr; 77(2):346-352. PubMed ID: 33423619
[TBL] [Abstract][Full Text] [Related]
32. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
[TBL] [Abstract][Full Text] [Related]
33. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C; Fonrose X; Thomas F; Roth G; Jacquet E; Brice A; Chirica C; Farneti D; Frenoux C; Stanke-Labesque F; Gautier-Veyret E
Br J Clin Pharmacol; 2023 Aug; 89(8):2446-2457. PubMed ID: 36918744
[TBL] [Abstract][Full Text] [Related]
34. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
35. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
36. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
38. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
39. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
40. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
Nguyen DG; Morris SA; Chen A; Moore DC; Hanson SL; Larck C; Musselwhite LW; Turner JD; Salem ME; Kwange SO; Hamilton A; Steuerwald N; Patel JN
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
